US-listed drugs company Pfizer has agreed to acquire a 40% stake in Brazil-based generic drugmaker Laboratório Teuto Brasileiroa head of potential full acquisition from 2014.

Pfizer will make an upfront payment of R$400m ($240m) and Teuto will be eligible to receive a performance-based milestone payment.  Pfizer has an option to acquire the remaining 60% of Teuto’s shares beginning in 2014, while Teuto’s shareholders have a put option to sell their 60% stake to Pfizer beginning in 2015. Goldman Sachs advised Pfizer while Banco BTG Pactual acted for Teuto. 

The lawyers were Skadden Arps Slate Meagher & Flom and Pinheiro Neto Advogados for Pfizer and Machado Meyer Sendacz & Opice and Cleary Gottlieb counseled Teuto.

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?